AIM: To investigate the effects of moxibustion on down-regulation of the colonic epithelial cell apoptosis and repair of the tight junctions in rats with Crohn's disease (CD). METHODS: Sixty male Sprague-Dawley ra...AIM: To investigate the effects of moxibustion on down-regulation of the colonic epithelial cell apoptosis and repair of the tight junctions in rats with Crohn's disease (CD). METHODS: Sixty male Sprague-Dawley rats were randomly divided into a normal control (NC) group, a model control (MC) group, an herbs-partitioned moxibustion (HPM) group, a mild-warm moxibustion (MWM) group and a salicylazosulphapyridine (SASP) group, with 12 rats in each group. The CD model rats were treated with trinitrobenzene sulphonic acid to induce intestinal inflammation. The rats in the HPM and MWM groups were treated at the Tianshu (ST25) and Qihai (CV6) acupoints once daily for 14 d, and the SASP group was fed SASP twice daily for 14 d. No additional treatment was given to the MC and NC groups. Themicrostructure of the colonic epithelium was observed under a transmission electron microscope, the transepithelial resistance was measured using a shortcircuit current, colonic epithelial cell apoptosis was determined by terminal deoxynucleotidyl transferasemediated dUTP-biotin nick end labelling assay, and the expression of occludin, claudin-1 and zonula occludens-l (ZO-1) in the colonic epithelial junction was determined by Western blotting and immunofluorescence staining. RESULTS: Compared with the MC group, the microstructure of the colonic epithelial barrier was signifi-cantly improved in rats treated with HPM, MWM or SASP, meanwhile, the current flow was reduced signifi-cantly, with values of 168.20 ± 6.14 vs 99.70 ± 3.13, 99.10 ± 4.28 and 120.30 ± 3.65 mA, respectively (P = 0.001). However, the HPM and MWM groups had higher current flow rates than the SASP group (99.70 ± 3.13, 99.10 ± 4.28 vs 120.30 ± 3.65 mA, P = 0.001). The number of the apoptotic colonic epithelial cells in HPM, MWM and SASP groups was largely reduced (61.5 ± 16.91 vs 15.5 ± 8.89, 14.8 ± 6.27 and 24.7 ± 9.68, respectively (P = 0.001); and the expression of occlu- din, claudin-1 and ZO-1 in the MWM and HPM groups was signifi cantly enhanced (0.48 ± 0展开更多
AIM： To characterize the bifidobacterial microbiota of the colonic mucosa in patients with colon cancer, inflammatory bowel disease or diverticulitis. METHODS： A sample of the distal colonic mucosa was taken during ...AIM： To characterize the bifidobacterial microbiota of the colonic mucosa in patients with colon cancer, inflammatory bowel disease or diverticulitis. METHODS： A sample of the distal colonic mucosa was taken during surgery from a total of 34 patients, twenty-one with diagnosed colorectal cancer, nine with diverticulitis and four with inflammatory bowel disease, requiring surgery for their condition. Bacterial DNA was extracted from the resected mucosal samples and bifidobacterial mucosa-associated microbiota was qualitatively and quantitatively determined by means of qualitative and quantitative PCR. RESULTS： Bifidobacteria were found in 100% of the samples from patients with diverticulitis or IBD and a 76% of those suffering colon cancer. The species B. Iongum and B. bifidum were the most widely found, followed by B. animalis, B. catenulatum and B. adolescentis. B. breve, B. dentium and B. angulatum were not detected in any sample. A significantly higher occurrence of B. Iongum was observed in patients with diverticulitis than in those with colon cancer or IBD （100%, 62% and 75%, respectively, P 〈 0.05）. Similar results were obtained for B, animalis （56%, 0% and 25%, P 〈 0.05）, while B. adolescentis was only found in the mucosa from patients with colon cancer （5 out of 21, 24%）. At the quantitative level, patients with colon cancer or IBD showed lower counts of total Bifidobacterium （4.94 and 5.91 vs 6.96 log Cells/sample, respectively, P 〈 0.05） and of the species B. longum （4.05 and 4.79 vs 6.76, P 〈 0.05） than those with diverticulitis.CONCLUSION： Aberrancies in mucosa associated microbiota are present in different intestinal diseases. This may indicate a role of the microbiota in the pathogenesis of these diseases.展开更多
目的观察针药并用治疗腹泻型肠易激综合征(diarrhea-irritable bowel syndrome,IBS-D)肝郁脾虚证的临床疗效以及对患者血清5-羟色胺(5-hydroxytryptamine,5-HT)、降钙素基因相关肽(calcitonin gene related peptide,CGRP)以及内皮素(end...目的观察针药并用治疗腹泻型肠易激综合征(diarrhea-irritable bowel syndrome,IBS-D)肝郁脾虚证的临床疗效以及对患者血清5-羟色胺(5-hydroxytryptamine,5-HT)、降钙素基因相关肽(calcitonin gene related peptide,CGRP)以及内皮素(endothelin,ET)的影响。方法选择60例IBS-D(肝郁脾虚证)患者作为研究对象,将患者随机分为观察组和对照组,每组30例。观察组患者采用针刺配合白术芍药散加减进行治疗,对照组仅采用针刺治疗。观察记录两组患者治疗总有效率、治疗前后中医临床症状积分差异以及IBS-D治疗前后专用生活质量量表(diarrhea-irritable bowel syndrome quality of life scale,IBS-QOL)评分差异以及两组患者治疗前后血清中5-HT、CGRP以及ET水平差异。结果观察组总有效率为83.3%,显著高于对照组的63.3%(P<0.05);治疗前两组患者中医临床症状总积分、各临床症状症状积分及IBS-QOL评分比较差异均无统计学意义(P>0.05);两组患者治疗后中医临床症状总积分、各临床症状症候积分及IBS-QOL评分与同组治疗前比较均显著降低(P<0.05);治疗后观察组中医临床症状总积分、IBS-QOL评分及治疗后3个月随访中医临床症状总积分、IBS-QOL评分与对照组比较均显著降低(P<0.05);治疗后观察组各种临床症状症状积分与对照组比较,均显著降低(P<0.05);治疗前两组患者血清中5-HT、CGRP以及ET水平比较差异无统计学意义(P>0.05);两组患者治疗后5-HT、CGRP以及ET水平与同组治疗前比较均显著降低(P<0.05);治疗后观察组5-HT、CGRP以及ET水平与对照组比较,显著降低(P<0.05)。结论针药并用治疗IBS-D(肝郁脾虚证)能够有效缓解患者临床症状,提高其生活质量,其作用机制可能是通过降低患者血清中的5-HT、CGRP以及ET水平来达到治疗的作用。展开更多
基金Supported by National Natural Science Foundation of China,No. 30772831National Basic Research Program of China, 973program, No. 2009CB522900Shanghai Leading Discipline Project, No. S30304
文摘AIM: To investigate the effects of moxibustion on down-regulation of the colonic epithelial cell apoptosis and repair of the tight junctions in rats with Crohn's disease (CD). METHODS: Sixty male Sprague-Dawley rats were randomly divided into a normal control (NC) group, a model control (MC) group, an herbs-partitioned moxibustion (HPM) group, a mild-warm moxibustion (MWM) group and a salicylazosulphapyridine (SASP) group, with 12 rats in each group. The CD model rats were treated with trinitrobenzene sulphonic acid to induce intestinal inflammation. The rats in the HPM and MWM groups were treated at the Tianshu (ST25) and Qihai (CV6) acupoints once daily for 14 d, and the SASP group was fed SASP twice daily for 14 d. No additional treatment was given to the MC and NC groups. Themicrostructure of the colonic epithelium was observed under a transmission electron microscope, the transepithelial resistance was measured using a shortcircuit current, colonic epithelial cell apoptosis was determined by terminal deoxynucleotidyl transferasemediated dUTP-biotin nick end labelling assay, and the expression of occludin, claudin-1 and zonula occludens-l (ZO-1) in the colonic epithelial junction was determined by Western blotting and immunofluorescence staining. RESULTS: Compared with the MC group, the microstructure of the colonic epithelial barrier was signifi-cantly improved in rats treated with HPM, MWM or SASP, meanwhile, the current flow was reduced signifi-cantly, with values of 168.20 ± 6.14 vs 99.70 ± 3.13, 99.10 ± 4.28 and 120.30 ± 3.65 mA, respectively (P = 0.001). However, the HPM and MWM groups had higher current flow rates than the SASP group (99.70 ± 3.13, 99.10 ± 4.28 vs 120.30 ± 3.65 mA, P = 0.001). The number of the apoptotic colonic epithelial cells in HPM, MWM and SASP groups was largely reduced (61.5 ± 16.91 vs 15.5 ± 8.89, 14.8 ± 6.27 and 24.7 ± 9.68, respectively (P = 0.001); and the expression of occlu- din, claudin-1 and ZO-1 in the MWM and HPM groups was signifi cantly enhanced (0.48 ± 0
文摘AIM： To characterize the bifidobacterial microbiota of the colonic mucosa in patients with colon cancer, inflammatory bowel disease or diverticulitis. METHODS： A sample of the distal colonic mucosa was taken during surgery from a total of 34 patients, twenty-one with diagnosed colorectal cancer, nine with diverticulitis and four with inflammatory bowel disease, requiring surgery for their condition. Bacterial DNA was extracted from the resected mucosal samples and bifidobacterial mucosa-associated microbiota was qualitatively and quantitatively determined by means of qualitative and quantitative PCR. RESULTS： Bifidobacteria were found in 100% of the samples from patients with diverticulitis or IBD and a 76% of those suffering colon cancer. The species B. Iongum and B. bifidum were the most widely found, followed by B. animalis, B. catenulatum and B. adolescentis. B. breve, B. dentium and B. angulatum were not detected in any sample. A significantly higher occurrence of B. Iongum was observed in patients with diverticulitis than in those with colon cancer or IBD （100%, 62% and 75%, respectively, P 〈 0.05）. Similar results were obtained for B, animalis （56%, 0% and 25%, P 〈 0.05）, while B. adolescentis was only found in the mucosa from patients with colon cancer （5 out of 21, 24%）. At the quantitative level, patients with colon cancer or IBD showed lower counts of total Bifidobacterium （4.94 and 5.91 vs 6.96 log Cells/sample, respectively, P 〈 0.05） and of the species B. longum （4.05 and 4.79 vs 6.76, P 〈 0.05） than those with diverticulitis.CONCLUSION： Aberrancies in mucosa associated microbiota are present in different intestinal diseases. This may indicate a role of the microbiota in the pathogenesis of these diseases.
文摘目的观察针药并用治疗腹泻型肠易激综合征(diarrhea-irritable bowel syndrome,IBS-D)肝郁脾虚证的临床疗效以及对患者血清5-羟色胺(5-hydroxytryptamine,5-HT)、降钙素基因相关肽(calcitonin gene related peptide,CGRP)以及内皮素(endothelin,ET)的影响。方法选择60例IBS-D(肝郁脾虚证)患者作为研究对象,将患者随机分为观察组和对照组,每组30例。观察组患者采用针刺配合白术芍药散加减进行治疗,对照组仅采用针刺治疗。观察记录两组患者治疗总有效率、治疗前后中医临床症状积分差异以及IBS-D治疗前后专用生活质量量表(diarrhea-irritable bowel syndrome quality of life scale,IBS-QOL)评分差异以及两组患者治疗前后血清中5-HT、CGRP以及ET水平差异。结果观察组总有效率为83.3%,显著高于对照组的63.3%(P<0.05);治疗前两组患者中医临床症状总积分、各临床症状症状积分及IBS-QOL评分比较差异均无统计学意义(P>0.05);两组患者治疗后中医临床症状总积分、各临床症状症候积分及IBS-QOL评分与同组治疗前比较均显著降低(P<0.05);治疗后观察组中医临床症状总积分、IBS-QOL评分及治疗后3个月随访中医临床症状总积分、IBS-QOL评分与对照组比较均显著降低(P<0.05);治疗后观察组各种临床症状症状积分与对照组比较,均显著降低(P<0.05);治疗前两组患者血清中5-HT、CGRP以及ET水平比较差异无统计学意义(P>0.05);两组患者治疗后5-HT、CGRP以及ET水平与同组治疗前比较均显著降低(P<0.05);治疗后观察组5-HT、CGRP以及ET水平与对照组比较,显著降低(P<0.05)。结论针药并用治疗IBS-D(肝郁脾虚证)能够有效缓解患者临床症状,提高其生活质量,其作用机制可能是通过降低患者血清中的5-HT、CGRP以及ET水平来达到治疗的作用。
